Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer

MLA

Gregory B. Lesinski, et al. “Anti-IL-6 and PD-L1 Antibody Combination Therapy Reduces Tumor Progression in Murine Models of Pancreatic Cancer.” Journal for ImmunoTherapy of Cancer, vol. 3, no. Suppl 2, p. P366. EBSCOhost, https://doi.org/10.1186/2051-1426-3-s2-p366. Accessed 4 Dec. 2024.

APA

Gregory B. Lesinski, Shannon Loftus, Thomas Ludwig, Reena Shakya, Mark Bloomston, Michael C. Ostrowski, Jason R. Pitarresi, Thomas A. Mace, Teresa A. Zimmers, Tanios Bekaii-Saab, Benjamin Swanson, Gregory S. Young, & Xioling Zhong. (n.d.). Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer. Journal for ImmunoTherapy of Cancer, 3(Suppl 2), P366. https://doi.org/10.1186/2051-1426-3-s2-p366

Chicago

Gregory B. Lesinski, Shannon Loftus, Thomas Ludwig, Reena Shakya, Mark Bloomston, Michael C. Ostrowski, Jason R. Pitarresi, et al. 2024. “Anti-IL-6 and PD-L1 Antibody Combination Therapy Reduces Tumor Progression in Murine Models of Pancreatic Cancer.” Journal for ImmunoTherapy of Cancer 3 (Suppl 2): P366. Accessed December 4. doi:10.1186/2051-1426-3-s2-p366.